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Objective. To assess associations of Chlamydia trachomatis and Mycoplasma genitalium antibodies with epithelial ovarian tumors.
Methods. Plasma samples from 291 women, undergoing surgery due to suspected ovarian pathology, were analyzed with respect to
C. trachomatis IgG and IgA, chlamydial Heat Shock Protein 60-1 (cHSP60-1) IgG and M. genitalium IgG antibodies. Women with
borderline tumors (n = 12), ovarian carcinoma (n = 45), or other pelvic malignancies (n = 11) were matched to four healthy
controls each. Results. Overall, there were no associations of antibodies with EOC. However, chlamydial HSP60-1 IgG antibodies
were associated with type II ovarian cancer (P = .002) in women with plasma samples obtained >1 year prior to diagnosis (n = 7).
M. genitalium IgG antibodies were associated with borderline ovarian tumors (P = .01). Conclusion. Chlamydial HSP60-1 IgG
and M. genitalium IgG antibodies are in this study associated with epithelial ovarian tumors in some subsets, which support the
hypothesis linking upper-genital tract infections and ovarian tumor development.
1.Introduction
Ovarian cancer is the sixth most common cancer among
females and the most lethal gynaecologic malignancy with
a 16–51% ﬁve-year survival rate globally [1]. No ﬁrm
conclusions are established on the etiology of ovarian cancer,
while 5–10% are attributable to genetic predisposition [2,
3]. Microorganisms causing chronic inﬂammatory disease
have become increasingly investigated in the last decade
as possible cancer initiators/promoters. Helicobacter pylori
has been linked to gastric cancer, human papillomavirus to
cervical cancer, and Hepatitis B and C virus to liver cancer
[4]. Chlamydia trachomatis (C. trachomatis) is considered
a cofactor in cervical cancer and is primarily associated
with squamos cell carcinoma of the cervix [5–7]. The role
of persistent infection, leading to chronic inﬂammation, in
the pathogenesis of ovarian cancer has received very little
consideration, although a history of pelvic inﬂammatory
disease (PID) is in a case-control study correlated to higher
riskforovariancancer[8].C.trachomatis,themostcommon
cause of PID in the developed world [9–11], is the genital
infectious agent that has most often been addressed as a
possible tumor initiator/promoter of the ovaries [12–15].
Primary infection with C. trachomatis, the most preva-
lent sexually transmitted bacterium worldwide with an
estimated 90 million new cases occurring each year [16], is
often asymptomatic and may persist for several months or
years [17]. There is evidence that chlamydial bacteria express
high levels of chlamydial heat shock protein 60 (cHSP60),
suggested to be antiapoptotic, during persistent infections
[18, 19], and serum cHSP60 IgG antibodies are in several
studies associated with tubal factor infertility (TFI) [20–24].
Mycoplasma genitalium (M. genitalium) is another sexually
transmitted microorganism that has been associated with2 Infectious Diseases in Obstetrics and Gynecology
PID and TFI [25, 26]. Similar to C. trachomatis infections,
disease caused by M. genitalium is often asymptomatic and it
often remains undetected [27].
It has been proposed that ovarian tumors can be
classiﬁed into two groups, type I and type II, based on
clinical behavior, pathology, molecular genetic diﬀerences,
and diﬀerent precursors [28, 29]. Type II tumors consti-
tute most ovarian carcinomas and are rapidly growing,
highly aggressive neoplasms that lack well-deﬁned precursor
lesions.ManyofthetypeIItumors,aresuggestedtooriginate
in the tubal ﬁmbria or peritoneum [30], are associated with
tubal intraepithelial carcinoma (TIC) and “p53 signatures”
and originate in the secretory cells [31]. Both C. trachomatis
and M. genitalium are especially adept at maintaining long-
term relationships with their hosts, modulating and evading
the immune system, and are shown to cause infections
and inﬂammation of the fallopian tubes [32–34]. Hence,
there is a possibility that these infections might play a
role in carcinogenesis of the ovary, particularly the type II
carcinomas [35].
Given the incomplete biological explanations for the
etiology of ovarian cancer and the hypothesis of chronic
infection and inﬂammation as part of ovarian tumor
pathogenesis we estimated the associations of plasma C.
trachomatis IgG, IgA, and cHSP60 IgG and plasma M.
genitalium IgG antibodies with ovarian tumors.
2.MaterialsandMethods
Thisstudyisinpartacohortstudytocomparetheprevalence
of antibodies in women with diﬀerent diagnoses going
through surgery due to suspected ovarian pathology, and in
partacase-controlstudytocomparetheantibody prevalence
in women with ovarian tumors with matched controls. The
study is approved by the Human Ethics Committee of the
Medical Faculty, Ume˚ a University, Sweden.
2.1. Study Population. From 1993 through 2001, 430 women
who underwent surgery at the Department of Obstetrics and
Gynecology, University Hospital of Ume˚ a, Sweden, due to
suspected ovarian pathology were included in the study after
oral and written informed consent. The women were mainly
from V¨ asterbotten County in northern Sweden. In 238 cases,
plasma samples drawn in connection with surgery were
available. For another 53 cases, prospective plasma samples
(maximum 5.1 years prior to diagnosis) from the Northern
Sweden Health and Disease Study (NSHDS) were available
and included in the analyses. In total, plasma samples were
available for 291 women (Figure 1). In cases of borderline
ovarian tumors (BOT), epithelial ovarian cancer (EOC),
and other malignancies, control plasma samples from the
Medical Biobank of Northern Sweden were matched with
respect to age (±1 year) and date of plasma-sampling (±3
months). Age criteria had to be relaxed to ±2y e a r si n4 9
out of 271 controls (18%), date of plasma-sampling to ±6
months in 4 controls (1%) and both age and date of plasma-
sampling in 4 controls (1%). The control plasma samples
were collected as part of the NSHDS, which is a population-
based, prospective health survey cohort in V¨ asterbotten
County, which has been previously reported in detail [36].
The NSHDS serves the same population as the University
Hospital of Ume˚ a regarding ovarian tumor surgery. Control
subjects were alive and without a cancer diagnosis (except
basalioma)atthetimeofthediagnosisoftheindexcase.Four
matched controls per case were analyzed.
2.2. C. trachomatis Antibody Analyses. C. trachomatis-
speciﬁc IgG and IgA antibodies, as well as Chlamydia
pneumoniae (C. pneumoniae) IgG antibodies, were deter-
mined by the microimmunoﬂuorescence (MIF) test (MRL
Diagnostics/Focus,Cypress,CA,USA)speciﬁcforserovarD-
K, according to the instructions of the manufacturer. Brieﬂy,
plasma dilutions at 1/40 (IgG) and 1/16 (IgA) were used. A
weak speciﬁc immunoﬂuorescence signal in the 1/40 (IgG)
and 1/16 (IgA) dilution was reported as positive in 1/20 and
1/8,respectively.DetectionofcHSP60typeI(cHSP60-1)IgG
antibodies was performed using the commercial cHSP60-
1 IgG ELISA technique (Medac, Germany). Protocol and
validation criteria of the assay were followed according to
themanufacturer’sinstructions.Brieﬂy,patientplasmaswere
diluted 1/50 and tested in duplicate. Cut oﬀ was deﬁned as
the mean optical density (OD) value of the negative control
plus 0.350 and results are presented as plus (+) or minus
(−). Plasma presenting OD values ±10% of the cut oﬀ value
were interpreted as indeterminant and were excluded from
analysis.
2.3. M. genitalium Antibody Analysis. M. genitalium IgG
antibodies were detected using a M. genitalium Lipid asso-
ciated membrane protein-enzyme immuno assay (LAMP-
EIA) as previously described [37]. Brieﬂy, 100µL of plasma
samples diluted 1/50 in blocking solution was used. Serum
from a patient with a M. genitalium—PCR positive result in
the urogenital tract specimen was used as a positive control,
and pooled sera from blood donors were used as a negative
c o n t r o li ne a c hr u n .T h ec u to ﬀ level was set to 0.3 OD and
was determined as 3-standard deviations above the negative-
control mean.
2.4. Clinical Characteristics and Histopathologic Diagnosis.
Information on histopathologic diagnosis, according to the
World Health Organization classiﬁcation [38], as well as
data on clinical characteristics, was extracted from the
medicalrecords.Histopathologicdiagnoseswerereviewedby
a specialist in gynecologic pathology (EL) at the Department
of Laboratory Medicine, Clinical Pathology, University Hos-
pital of Ume˚ a. A reclassiﬁcation according to the proposed
hypothesis of a type I and a type II ovarian pathogenetic
pathway [29] was done. The type I tumor group consisted of
low-grade serous carcinomas and mucinous, endometrioid
and clear cell carcinomas. The type II tumor group consisted
of ovarian moderate and high-grade serous carcinomas,
malignant mixed mesodermal tumors and undiﬀerentiated
carcinomas, as well as serous high-grade or undiﬀerentiated
peritoneal and fallopian tube cancers.Infectious Diseases in Obstetrics and Gynecology 3
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Figure 1: Study cohort originating from women who underwent surgery due to suspected ovarian pathology. aNumber of women in the
diﬀerent diagnose groups in whom plasma samples were obtainable. bNumber of women for whom 4 matched controls per case were
obtainable. cControls from the NSHDS (Northern Sweden Health and Disease Study) matched with respect to age and time of plasma-
sampling.
2.5. Statistical Analysis. Statistical analyses were performed
using the SPSS software (version 17.0). The pearson Chi-
square, and when the expected frequency was <5, Fisher’s
exact test was used to analyze diﬀerences between groups
with dichotomous data. Fisher’s exact conﬁdence intervals
were calculated for the prevalence estimates. Mann-Whitney
U test was applied to analyze continuous data not normally
distributed. A 2-sided P value of less than .05 was considered
signiﬁcant. Odd ratios (OR) and 95% conﬁdence intervals
(CI) were calculated using binary logistic regression analysis.
3. Results
Clinical characteristics of the women going through ovarian
surgery are described in Table 1. Demographic data are
not complete, as indicated in the table, particularly among
women with benign conditions, but the antibody prevalence
was similar in women with or without demographic data.
However, women with data on hormone replacement ther-
apy (HRT) use presented C. trachomatis IgG (P = .023)
and cHSP60-1 IgG (P = .008) more often than women
lacking these data. Women with HRT data were younger
(P = .006). Women with PID data more often presented C.
trachomatis IgG (P = .046) and cHSP60-1 IgG (P = .011)
antibodies. C. trachomatis IgG antibodies were associated
with ever smoking (P<. 001) and HRT use (P = .02),
while cHSP60-1 IgG antibodies were associated with ever
smoking (P = .003) and older age at menarche (P =
.018). No other associations of antibodies with demographic
data were found.
Caseswherenoplasmasamplesorcontrolswereavailable
(Figure 1) had the same distribution of diagnoses as cases
with matched controls. Reasons for lacking a plasma sample
were mostly due to human error when including women
about to have surgery. Diﬃculties in ﬁnding controls depend
either on high age (>72 years) of the case (n = 9) and/or a
plasma sample from the ﬁrst years of the study (1993–1995)
(n = 5). No diﬀerences were found in the prevalence of
antibodies between cases with or without matched controls.
The prevalence of C. pneumoniae IgG antibodies was
79.8% (95% CI: 76.2%–82.4%) and no covariations of C.
trachomatis IgG, IgA, or cHSP60-1 IgG antibodies with C.
pneumoniae IgG antibodies were found. C. trachomatis IgG
and cHSP60-1 IgG antibodies were associated with a 74%
concordance rate.
The prevalence of C. trachomatis IgG, cHSP60-1 IgG,
and M. genitalium IgG antibodies among all women tested,
including matched controls, are given in Table 2.
Notably, there is a signiﬁcantly higher prevalence of M.
genitalium IgG antibodies among women with borderline
tumors compared with matched controls and women with
benign conditions. Three of the four cases positive in M.
genitalium IgG were also positive in cHSP60-1 IgG. In the
subgroupofovariancancercasesthathadprospectiveplasma
samples collected more than one year prior to diagnosis
(n = 11), cHSP60-1 IgG antibodies were more prevalent
among cases compared with women with benign conditions.
The prevalence of plasma C. trachomatis IgA antibodies
among all cases was 9.6% (95% CI: 6.5%–13.6%) with no
association with ovarian tumors.
The antibody prevalences among women with type I
tumors, or any of the histological subgroups of EOC, were
not raised compared with neither matched controls nor wo-
men with benign conditions when plasma samples drawn in4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Clinical characteristics for the women (291) with benign conditions, borderline ovarian tumors, epithelial ovarian cancer, or other
pelvic malignancies included in the plasma antibody analyses.
Clinical
characteristics
Benign conditions
(n = 209) BOT (n = 16) EOC (n = 54) Other pelvic malignancies
(n = 12)
BOT
versus
benign,
P value
EOC
versus
benign,
P value
Age, y 52 (18–87) 53 (40–82) 61 (31–78) 58 (40–73) 1.0b .003b
Menarchea, y 13 (10–16), n = 69 13 (11–14), n = 4 13 (11–17), n = 51 13 (11–16), n = 8. 9 b .06b
Menopausea, y 50 (40–57), n = 93 50 (44–54), n = 7 50 (43–61), n = 41 50 (41–55), n = 71 . 0 b .2b
Paritya 2 (0–8), n = 186 2 (0–4), n = 14 2 (0–5), n = 54 3 (0–3), n = 11 .6b .8b
0 childrena 37 (20%), n = 186 1 (7%), n = 14 12 (22%) 1 (9%), n = 11 .5c .7d
≥3 childrena 49 (26%), n = 186 3 (21%), n = 14 14 (26%) 6 (54%), n = 11 1.0c .9d
Oral contraceptive
pill use ≥1 yeara 61 (73%), n = 84 4 (80%), n = 5 17 (37%), n = 46 1 (12%), n = 81 . 0 c <.001d
Past or current
HRT usea 37 (24%), n = 152 3 (27%), n = 11 14 (27%), n = 52 2 (18%), n = 11 .7c .2d
Past or current
smokinga 54 (30%), n = 183 6 (50%), n = 12 18 (33%), n = 54 4 (36%), n = 11 .2c .6d
History of PIDa 12 (34%), n = 35 1 (14%), n = 74 ( 9 % ) , n = 43 0 (0%), n = 9. 4 c .007d
BMIa 26 (19–41), n = 41 24 (21–28), n = 5 25 (17–34), n = 53 26 (19–30), n = 11 .4b .5b
Prospective plasma
sample >1 year
prior to diagnosis
22 (11%) 0 11 (20%) 1 (8%)
Histology
Serous n = 52 n = 9 n = 32 SSPC, n = 7
Mucinous n = 35 n = 7 n = 5
Endometrioid n = 26 n = 0 n = 10
Tubal cancer, n = 1
Uterine cancer, n = 1
Abdominal cancer, n = 1
Follicle cyst, n = 39
Brenner tumor, n = 1
Theca cell tumor, n = 1
Fibroma, n = 6
Corpus luteum cyst, n = 2
Extra uterine pregnancy,
n = 3
Tubo-ovarian abcess/sacto
salpinx, n = 6
Endometriosis, n = 6
Gastrointestinal
inﬂammation, n = 3
Other, n = 14
Normal, n = 15
Mixed EOC, n = 1
Undiﬀerentiated
EOC, n = 4
Clear cell tumor,
n = 2
Undiﬀerentiated tubal
cancer, n = 1
Undiﬀerentiated
abdominal cancer, n = 1
Type 1
pathogenetic
pathway
19 (35%) 3 (25%)
Type 2
pathogenetic
pathway
35 (65%) 9 (75%)
Values are presented as medians and range (minimum and maximum values of age, menarche, menopause, parity, and BMI); or number and percentage
of patients in each group (0 children, ≥3 children, oral contraceptive pill use ≥1 year, past or current HRT use, past or current smoking, history of PID:
prospective plasma samples>1 year prior to diagnosis, type I pathogenetic pathway, and type II pathogenetic pathway).
BOT: borderline ovarian tumor; EOC: epithelial ovarian cancer; HRT: hormone replacement therapy; PID: pelvic inﬂammatory disease; BMI: body mass
index; SSPC: Serous Surface Papillary Carcinoma.
aVariable with partial missing data.
bMann-Whitney U test.
cFisher’s exact test.
dChi-Square test.Infectious Diseases in Obstetrics and Gynecology 5
Table 2: Prevalence of plasma antibodies in women with borderlineovarian tumors,epithelial ovarian cancer, and other pelvic malignancies
compared with matched controls and women with benign conditions.
Tumors and
antibodies analyzed
Antibody-positive n (%)
Casesa
versus
matched
controlsb,
P value
Antibody-positive n (%)
Cases versus
benign
conditions,
P value
BOT Casesa (n = 12) Matched controlsb (n = 48) Cases (n = 16) Benign conditions
(n = 209)
C. trachomatis IgG 4 (33%) 9 (19%) .3 5 (31%) 51 (24%) .5
cHSP60 IgG 4 (33%) 11 (23%) .5 5 (31%) 48 (24%), n = 202c .5
M. genitalium IgG 4 (33%) 2 (4%) .01 4 (25%) 17 (8%) .049
EOC Casesa (n = 45) Matched controlsb (n = 180) Cases (n = 54) Benign conditions
(n = 209)
C. trachomatis IgG 9 (20%) 26 (14%) .4 9 (17%) 51 (24%) .2
cHSP60 IgG 10 (22%) 38 (22%), n = 172c 1.0 13 (24%) 48 (24%), n = 202c 1.0
M. genitalium IgG 4 (9%) 6 (3%) .1 4 (7%) 17 (8%) 1.0
Other pelvic
malignancies Casesa (n = 11) Matched controlsb (n = 43) Cases (n = 12) Benign conditions
(n = 209)
C. trachomatis IgG 1 (9%) 8 (19%) .7 1 (8%) 51 (24%) .3
cHSP60 IgG 3 (27%) 10 (23%) 1.0 3 (25%) 48 (24%), n = 202c 1.0
M. genitalium IgG 0 1 (2%) 1.0 0 17 (8%) .6
EOC with prospective
plasma samplesd Casesa (n = 10) Matched controlsb (n = 40) Cases (n = 11) Benign conditions
(n = 209)
C. trachomatis IgG 2 (20%) 4 (10%) .6 2 (18%) 51 (24%) 1.0
cHSP60 IgG 6 (60%) 10 (26%), n = 38c .06 7 (64%) 48 (24%), n = 202c .008
M. genitalium IgG 0 (0%) 1 (2.5%) 1.0 0 (0%) 17 (8%) 1.0
BOT: borderline ovarian tumors; EOC: epithelial ovarian cancer.
aCases with matched controls available.
bFour controls per case from the NSHDS (Northern Sweden Health and Disease Study) were matched with respect to age and date of plasma-sampling.
cA few subjects had cHSP60 IgG antibody results that were indeterminant and therefore excluded from the statistical analyses. Assigning them extreme values
(all positive or negative) did not change the main outcomes.
dEpithelial ovarian cancer with plasma samples drawn 1.3 to 5.1 years prior to diagnosis.
Pearson Chi-square, and when the expected frequency was <5, Fisher’s exact test was used.
connection with diagnosis was analyzed (data not shown).
The results of the antibody analyses for the type II ovarian
tumors are described in Table 3. In plasma samples drawn
in connection with diagnosis in type II tumors, there was
no evidently higher prevalence of cHSP60-1 IgG antibodies
compared with matched controls or women with benign
conditions. However, when prospective plasma samples of
the type II tumor group (n = 7) were analyzed, the
prevalence of cHSP60-1 IgG antibodies was signiﬁcantly
higher than in controls. Six out of seven cases were cHSP60-
1 IgG antibody-positive. The clinical characteristics of this
subgroup are presented in Table 4. The one woman that was
cHSP60-1 IgG antibody-negative had an undiﬀerentiated
ovarian cancer. Assigning indeterminant cHSP60-1 IgG anti-
body results either positive or negative values did not change
the main outcomes.
4. Discussion
In this analysis of a cohort of women going through surgery
due to suspected ovarian pathology, we found an association
of plasma cHSP60-1 IgG antibodies with type II ovarian
tumors when prospective plasma samples were analyzed.
Additionally, an association of plasma M. genitalium IgG
antibodies with borderline ovarian tumors was detected.
Neither C. trachomatis IgG nor IgA was signiﬁcantly associ-
ated with any type of tumors in this cohort.
Strengthsofthisstudyarethepopulation-basedselection
of case and control subjects with controls matched with
respect to age and time of plasma-sampling. Moreover, the
cohort was relatively homogeneous, the collection and stor-
age of blood samples was standardized, the measurement
of antibodies was performed in a research laboratory with
laboratory personnel unaware of case-control status, the C.
trachomatis IgG and IgA antibody test method is serovariant
D-K speciﬁc, a standardized cHSP60-1 IgG test method was
used, and the M. genitalium IgG method has no cross-
reactivity to M. pneumoniae. Limitations of the study include
the small number of subjects with eligible plasma samples
and matched controls, making subgroup analysis and ana-
lysis of combinations of antibodies diﬃcult. Incomplete
data on clinical characteristics reduces the possibility to co-
rrect for potential confounders. However, the subgroup of6 Infectious Diseases in Obstetrics and Gynecology
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Table 4: Clinical characteristics of women with type II tumors and
plasma samples drawn 1.3–5.1 years prior to diagnosis.
Clinical characteristics
Type II tumors with
prospective plasma samples
(n = 7)
Age, y 62 (56–69)
Menarche, y 14 (12–16)
Menopause, y 50 (41–60)
Parity 3 (0–5)
0 children 2 (29%)
≥3 children 4 (57%)
Oral contraceptive pill use ≥1
yeara 2 (33%), n = 6
Past or current HRT use 2 (29%)
Past or current smoking 2 (29%)
History of PID 2 (29%)
BMI 26 (20–31)
Histology
Serous ovarian cancer 4
Mixed epithelial ovarian cancer 1
Undiﬀerentiated ovarian cancer 1
SSPC 1
Valuesarepresentedasmediansandrange(minimumandmaximumvalues
of age, menarche, menopause, parity, and BMI); or number and percentage
of patientsin each group (0 children, ≥3 children, oral contraceptive pill use
≥1 year, past or current HRT use, past or current smoking, history of PID).
HRT: hormone replacement therapy; PID: pelvic inﬂammatory disease;
BMI: body mass index; SSPC: Serous Surface Papillary Carcinoma.
aMissing data in one case.
women with type II carcinoma and prospectively drawn
plasma samples did not seem to stand out concerning their
clinical characteristics. The plasma samples in cases were
mostly drawn within a few days prior to surgery. Analyzing
plasma samples drawn more than one year prior to diagnosis
might have been a more plausible approach considering the
result of the subgroup analysis of cases with prospectively
drawn plasma samples and previous studies regarding C.
trachomatis and cervical cancer [39–41].
TheassociationofcHSP60-1IgGantibodieswithovarian
cancer, and the slightly higher prevalence of C. trachomatis
IgG antibodies, is consistent with the ﬁndings of an associa-
tion of high levels of serum C. trachomatis IgG and cHSP60-
1 IgG antibodies with ovarian cancer in a population-based
case-controlstudy [13].Wong et al.,however, did not ﬁndan
association of Chlamydia serum IgG, IgA, or IgM antibodies
with epithelial ovarian cancer [15], maybe because the test
method applied was not C. trachomatis speciﬁc and detected
antibodiestoallchlamydialspeciesincludingC.pneumoniae.
Serum C. trachomatis IgG antibodies were not associated
with ovarian cancer in the recent study by Ness et al.
[14], rather, a protective eﬀect in younger-age groups was
found. In that study, serum samples obtained after cancer
treatment were analyzed possibly masking an association.
Chlamydial HSP60-1 IgG antibodies were the antibodies
most clearly associated with ovarian type II tumors in this
study. Chlamydial HSP60 expression is found to be increased
in prolonged infections with C. trachomatis and is suggested
to have an antiapoptotic eﬀect. This eﬀect facilitates the
survival of the bacteria within the host [18, 19], but at the
same time it facilitates the survival of DNA-damaged cells
leading to increased risk for cancer initiation [42].
The subgroup of women with prospectively drawn
plasma samples displayed larger diﬀerences in antibody pre-
valence between cases and controls than women with plasma
samples drawn at the time of diagnosis. Similar to this,
concerning cervical cancer, Naucler et al. observed a positive
correlation between C. trachomatis IgG antibodies and cases
observed during followup, but not with cases identiﬁed at
baseline [39]; cHSP60-1 IgG antibodies have been associated
with cervical cancer in cases with long lag time [40]; and
C. trachomatis DNA in Pap smears taken many years before
diagnosis have been associated with cervical cancer [41]. A
conceivable explanation for this might be that C. trachomatis
exerts its eﬀect many years, or decades, before the cancer is
overt and that antibodies might decline over time [43–46].
Type II tumors are suggested to originate in the secretory
cells of the tubal ﬁmbria in a signiﬁcant percentage of
tumors [30, 31, 47, 48]. The secretory cells are the cell
type where chlamydial inclusions have been detected in
experimental models [49, 50] and the bacteria are known
to cause damage to the tubal ﬁmbria. Therefore, it seems
plausible that this subgroup was the one associated with
cHSP60-1 IgG antibodies. However, the subgroup of women
with prospective plasma samples was small, which will raise
concern that this result is due to chance.
Plasma C. trachomatis IgA antibodies displayed varying
andlowprevalenceinallgroupsandwerenotassociatedwith
the ﬁnding of ovarian tumors. IgA antibodies, in contrast to
IgGandcHSP60-1IgG,aremorelikelytoreﬂectanactiveon-
going phase of the infection which might be passed several
years before the tumor is overt.
The association between M. genitalium IgG antibodies
and borderline ovarian tumors might represent a typeI error
since a Bonferroni correction eliminates the signiﬁcance
of the results. M. genitalium is not previously studied in
relation to ovarian cancer even though Mycoplasma DNA
(PCR targeting 15 diﬀerent species) was found in 59% of
ovarian cancer tissues [51]. On the other hand, in a study
by Quirk et al., Mycoplasma ribosomal DNA (11 diﬀerent
Mycoplasma species but not M. genitalium)w a sf o u n dn o t
associated with ovarian tumors [52]. In vitro, M. genitalium
can cause inﬂammatory changes of the epithelium to the
h u m a nF a l l o p i a nt u b e s[ 53].
The prevalence of cHSP60-1 IgG antibodies was in this
study relatively high compared with the prevalence of C.
trachomatis IgG antibodies, particularly in the subgroup
of women with type II carcinoma. This is diﬀerent from
the ﬁndings in most other studies and might reﬂect diﬀ-
erences in laboratory methods. Another explanation is that
the C. trachomatis, infections that will eventually lead to car-
cinomatous changes, produce higher amounts of cHSP60
or produces cHSP60 for a more protracted period of
time inducing the production of cHSP60-1 IgG antibodies.
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that leads both to the continuous production of cHSP60-
1 IgG antibodies and renders the host more susceptible
to carcinomatous changes. This might be the case, if for
example, an autoimmune cross-reaction to the human
HSP60 [54] has a pathological role to play.
In conclusion, we have identiﬁed an association of
plasmacHSP60-1IgGantibodieswithtypeIIovariantumors
in the subgroup of women with plasma samples drawn
more than one year prior to surgery. This novel ﬁnding
points toward another possible explanation of the etiology
of ovarian neoplasia. M. genitalium was weakly associated
with borderline ovarian tumors. Deﬁning C. trachomatis and
M. genitalium as disease precursors would have great impact
on the importance of preventing, diagnosing, and treating
C. trachomatis and M. genitalium infections to reduce not
only fertility related morbidity and chronic pelvic pain,
but also ovarian tumor development. However, the results
have to be conﬁrmed in larger studies and in studies with
prospective plasma samples, and the mechanisms by which
the bacteria might initiate or promote tumor development
havetobeclariﬁed.Nevertheless,thisstudyprovidessupport
to the intriguing hypothesis of a link between upper-genital
tract infectious agents such as C. trachomatis, possibly M.
genitalium, and ovarian tumor development.
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